Physician profile
Patrick A Egbe
NPI 1699762419
$1,463.47
in general payments reported to CMS, 2019-2025
21 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $102 · 2021: $127 · 2022: $177 · 2023: $251 · 2024: $250 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.60 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $262.15 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Pfizer INC. | $181.71 | 2022-2025 | |
| Bridgebio Pharma, INC. | $151.71 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $137.78 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.47 | 2019-2023 | Jardiance |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $81.04 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $69.56 | 2022-2024 | |
| Scpharmaceuticals INC. | $49.00 | 2024-2025 | |
| Amarin Pharma, INC. | $39.48 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $36.38 | 2023-2025 | Verquvo |
| Medela LLC | $31.75 | 2020 | |
| Esperion Therapeutics, INC. | $29.79 | 2020-2021 | |
| Abiomed | $29.02 | 2025 | |
| Boston Scientific Corporation | $28.68 | 2025 | Bodyguardian |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.94 | 2022 | |
| Cardiva Medical, INC. | $21.18 | 2022 | |
| Amgen INC. | $20.87 | 2025 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $17.57 | 2022 | |
| Impulse Dynamics (USA) INC. | $14.30 | 2023 | Optimizer |
| Medtronic Vascular, INC. | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Egbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.